The CD300 family of molecules modulates a broad and diverse array of immune cell processes via their paired activating and inhibitory receptor functions. The description that CD300 molecules are able to recognize lipids, such as extracellular ceramide, phosphatidylserine (PS) and phosphatidylethanolamine (PE), that are exposed on the outer leaflet of the plasma membrane of dead and activated cells, has opened a new field of research. Through their binding to lipids and other ligands, this family of receptors is poised to have a significant role in complex biological processes and in the host response to severe pathological conditions. Indeed, published data have demonstrated their participation in the pathogenesis of several disease states. Moreover, this family of receptors has great potential as targets for diagnosis and therapeutic purposes in infectious diseases, allergy, cancer, and other pathological situations. For instance, one member of the family, CD300a, has been studied as a possible biomarker. Here, a review is provided on the cellular distribution of the human and mouse families of receptors, the stimuli that regulate their expression, their ability to tune leukocyte function and immune responses, their signaling pathways, ligand recognition, and their clinical relevance.
Introduction
In order to provide an adequate response that allows the elimination of insults while preserving self, the immune system is tightly regulated by a balance between activating and inhibitory signals. Multiple mechanisms exist to accomplish this task, including the expression of activating and inhibitory receptors by immune cells. [1] [2] [3] [4] [5] In general, the inhibitory receptors carry immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplasmic tail, 2, 4 whereas their activating counterparts have a charged residue in their transmembrane segments that facilitates the interaction with adaptor proteins carrying immunoreceptor tyrosine-based activating motifs (ITAMs) or phosphatidylinositol 3-kinases (PI3K) binding motif (YxxM). 2, 6 The human CD300 multigene family has seven members located on chromosome 17. [7] [8] [9] They were named alphabetically according to the order of their location in the chromosome. The mouse counterparts, which were reported as DC-derived Ig-like receptor (DIgR), 10 CMRF-35-like molecules (CLM), 11 leukocyte mono-Ig-like receptor (LMIR), 12 and myeloid associated Ig-like receptor (MAIR), 13 are encoded by nine genes located on mouse chromosome 11, the synthenic region of human chromosome 17. 9 The human-mouse CD300 orthologs have been identified by phylogenetic analysis and by their gene organization within the complex. 9 However, except for the two inhibitory receptors, i.e. CD300a and CD300f, all the others are not perfect functional orthologs.
For the purpose of clarity, and based on the published literature, this review will use the CD nomenclature for the human molecules and for the two murine ITIM containing receptors. For the rest of the mouse CD300 molecules the nomenclature is still very
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From confusing, and in this review sometimes a combination of names will be used when referring to the same receptor. Table I and Table II summarize the nomenclature these receptors have received since their discoveries. In Figure 1 , the genomic organization of the human and mouse CD300 complexes is represented according to the latest drafts provided by the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/gene) and the Mouse Genomic Informatics (http://www.informatics.jax.org). For the murine genes, the CD nomenclature has not been used for all the genes in Figure 1 , but it is shown in Table II. CD300 receptors are type I transmembrane proteins with a single IgV-like extracellular domain containing two disulfide bonds. 9, [14] [15] Only CD300a and CD300f have long cytoplasmic tails with ITIMs, while the other members have a short cytoplasmic tail, a charged transmembrane residue and associate with adaptor proteins such as DAP12, DAP10 and the FcRγ chain (FcεRIγ) 9 (Figure 2 ). One exception is CD300g, which is encoded by a gene mapped at some distance from the complex, lacks structural motifs suggestive of stimulatory or inhibitory potential, and in addition to the IgV-like domain, it has a mucin-like domain [16] [17] . CD300g is expressed in the vascular endothelial cells of high endothelial venules of lymph nodes, and supports lymphocyte rolling via the mucinlike domain, mediates lymphocyte binding through its Ig domain and promotes lymphocyte transendothelial migration in vitro. [16] [17] [18] For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From
Distribution, Mechanisms of Signaling and Modulation of Immune Functions
CD300 family members have the potential to form homo and heterodimers, which is dependent on their immunoglobulin domains. This implies, that in addition to the signal that originates from each single receptor, the formation of heterocomplexes adds another degree of complexity in the signaling pathways emanating from this family of receptors. [19] [20] Here, both the human and mouse ITIM containing CD300a and CD300f receptors will be jointly reviewed, since they can be considered as functional orthologs.
However, description of non-ITIM containing CD300 receptors from humans and mice will be discussed separately.
ITIM Containing CD300 Receptors
Transcripts encoding human CD300a are detected in myeloid and lymphoid cells. [21] [22] [23] [24] [25] [26] Nevertheless, the cell surface expression of CD300a has been somehow difficult to determine because a lack of mAbs able to distinguish between CD300a and CD300c. 23, 25, [27] [28] Human CD300a is expressed in all NK cells 22, 25 and in subsets of T and B cells. [27] [28] [29] [30] [31] On CD4 + T cells, the expression of CD300a is associated with Th1 cells that are more polyfunctional and after stimulation up-regulate the transcription factor Eomesodermin. [28] [29] On CD8 + T cells, CD300a expression is mostly associated with effector functions. 31 Naïve B cells express low levels of CD300a, whereas memory B cells and plasma cells express variable levels. 30 CD300a is also expressed on the surface of monocytes, plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells (mDCs), granulocytes, and cord blood derived mast cells (CBMC). 24, [32] [33] [34] [35] [36] For CD4 + T cells, stimulation with anti-CD3 plus anti-CD28 mAbs and Th1 differentiation conditions up- regulated cell surface expression of CD300a, whereas TGF-β1 exhibited a negative   regulatory effect. 27,29 TLR9 stimulation increased the cell surface expression of CD300a   on human memory B cells, while IL-4 and TGF-β1 were negative regulators. 30 LPS, IFNγ , IFN-α, and hypoxia conditions regulated the expression of CD300a in monocytes. 21, 37 In neutrophils, LPS and GM-CSF treatment caused a rapid translocation of an intracellular pool of CD300a to the cell surface. 32 It is quite possible that an intracellular pool of CD300a also exists in human basophils, which is translocated to the cell surface upon their stimulation through the FcεRI in just 1-3 minutes. 36 In pDCs, IFN-α production in response to TLR7 and TLR9 stimulation down-regulated the expression of CD300a, 24 and the eosinophil-derived proteins MBP and EDN down-regulated it on CBMC. 33 Transcripts encoding mouse CD300a are also found in lymphoid and myeloid cells. On the cell surface, mouse CD300a is expressed on the majority of myeloid cells, and on subsets of B cells, with higher expression on marginal zone B cells. [12] [13] However, opposed to human CD300a, it is not detected on the surface of unstimulated NK and T cells, and stimulation with IL-12 resulted in low expression of the receptor on NK cells. 13 Human CD300a has four tyrosine residues in its intracellular tail. Three of those tyrosines are within consensus sequences for classical or canonical ITIMs (I/V/LxYxxL/V) and the fourth is part of a non-classical or permissive ITIM (I/V/L/S/TxYxxL/V/I) ( Figure 2 ). 22, 38 The concept of non-classical or permissive ITIM includes the previously described immunoreceptor tyrosine-based switch motif or ITMS (TxYxxV/I). 38 The cytoplasmic
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From tail of mouse CD300a possesses two classical ITIMs, and a third tyrosine is within a tyrosine-based sorting motif. [12] [13] Tyrosine phosphorylation of the ITIMs is required for the transmission of the inhibitory signal, 25, [39] [40] and in CD300a transfected Jurkat cells the Src tyrosine kinase Lck is responsible for their phosphorylation. 39 Phosphorylated ITIMs are able to recruit different phosphatases depending on the examined cell type and the method of stimulation. 12, 22, 33, 35, 40 In SHP-2 and SHIP deficient DT40 B cells, CD300a was still able of inhibiting BCR-mediated signals. However, in cells deficient in SHP-1, the CD300a-mediated inhibition was largely abolished, indicating a dominant role for this phosphatase in CD300a-mediated signal. 39 Furthermore, only the pharmacological inhibition of SHP-1 was able to block the inhibitory function of CD300a. 41 In a more physiological setting, SHP-1 recruitment to mouse CD300a was observed when bone marrow-derived mast cells (BMMCs) and macrophages were mixed with apoptotic cells and treated with LPS. [42] [43] Apoptotic cells expose phopshatidylserine (PS) and phosphatidylethanolamine (PE), the two ligands of CD300a, in the outer leaflet of the plasma membrane. The dominant role of SHP-1 has been also demonstrated by knocking down SHP-1 expression in BMMCs from CD300a deficient mice. 43 Cross-linking of human CD300a with mAbs inhibited Ca ++ mobilization in response to BCR, 30 TCR, 28 FcεRI, 33, [44] [45] and FcγRIIa 32 mediated stimulation. It also inhibited NK cell-mediated cytotoxicity; 22, 25 B cell proliferation; 30 IgE-dependent mediator release from mast cells, SCF-mediated mast cell activation, differentiation and survival, and IgEmediated CD63 expression in basophils; 33, 36, [44] [45] eotaxin-induced eosinophil migration, and IL-5 and GM-CSF-induced eosinophil survival; 35 FcγRIIa-mediated reactive oxygen For personal use only. on November 16, 2017. by guest www.bloodjournal.org From species production by neutrophils; 32 and LPS and CpG-induced IL-8 secretion by the myelomonocytic THP-1 and U937 cell lines. 41 Cross-linking of CD300a also regulated TCR-mediated IFN-γ production, 28 and type I interferon and TNF-α secretion by pDCs in response to TLR7 and TLR9 stimulation. 24 Engagement of mouse CD300a with mAbs inhibited IgE-induced mediators release from BMMCs. 13 CD300a-/-BMMCs and macrophages treated with LPS in the presence of apoptotic cells produced higher levels of proinflammatory cytokines, indicating that CD300a acts as an inhibitory receptor in these cell types. 43 Human CD300f transcripts were detected in myeloid cells. [46] [47] On the cell surface, CD300f is expressed on monocytes, although is almost absent in monocytes from cord blood, and at low levels in circulating DCs, granulocytes and monocyte-derived DCs. 46, [48] [49] Interestingly, CD300f was markedly up-regulated in monocyte-derived DCs that were cultured in the presence of 1,25-Dihydroxyvitamin D 3 , which reprograms DCs to become tolerogenic, suggesting an important role for this receptor in maintaining a tolerogenic state. 50 Expression of CD300f was also found in the majority of acute myeloid leukemia (AML) samples obtained from patients. 48 Mouse CD300f transcripts are found in myeloid cells, including mast cells, and in B cells. 11, 51 Bone marrow (BM)-derived DCs also express abundant levels of CD300f transcripts, which are up-regulated by LPS and IL-10 treatment. 51 The cell surface expression of CD300f on neutrophils is up-regulated after LPS and GM-CSF stimulation, 52 and treatment with RANKL, a cytokine that drives osteoclast formation, down-regulates CD300f mRNA levels. 11 For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Human CD300f has five tyrosine-based motifs in the intracellular tail; two of them fit with classical ITIMs and a third with a non-classical ITIM. The other two tyrosines are within motifs reported to bind the p85α regulatory subunit of PI3K (YxxM), with one of them additionally fitting a growth factor receptor-bound protein 2 (Grb2) binding motif (YxN). 46, 53 Mouse CD300f has two classical ITIMs, a non-classical ITIM, a PI3K binding motif, and a Grb-2 binding motif. 11 As for CD300a, ITIM tyrosine phosphorylation is required for the CD300f-mediated inhibitory signal and phosphorylated ITIMs are able to recruit different phosphatases depending on the examined cell type. 11, [46] [47] [53] [54] The cross-linking of CD300f in THP-1 cells resulted in phosphorylation of SHP-1 and SHP-2, whereas the pharmacological inhibition of both phosphatases was able to block CD300f-mediated signals. 41, [55] [56] [57] In anti-TNP IgEsensitized BMMCs, co-engagement of FcεRI and mouse CD300f with TNP-BSA and ceramide, respectively, induced the tyrosine phosphorylation of CD300f, and the subsequent recruitment of SHP-1 and SHP-2, but not of SHIP. 58 Extracellular ceramide has been described as a natural ligand for mouse CD300f. 58 Engagement of CD300f with mAbs inhibited FcεRI-mediated degranulation. 53 On THP-1 cells, CD300f inhibited TLR2, TLR3, TLR4, TLR9 and BAFF induced expression of IL-8 and matrix metalloproteinase (MMP)-9. 41, [55] [56] Overexpression of CD300f in RAW cells inhibits in vitro osteoclast formation by RANKL and TFG-β, 11 and co-engagement of FcεRI and CD300f with mAbs in BMMCs impaired IL-6 production induced by FcεRI cross-linking alone. 54 In in vitro experiments, the cross-linking of mouse CD300f with its ligands ceramide, sphingosylphosphocholine (SPC), high-density lipoprotein (HDL), or
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From low-density lipoprotein (LDL), inhibited FcεRI mediated β -hexosaminidase release and IL-6 production. This inhibition was not observed when CD300f-/-BMMCs were used in the assay. 58 Using CD300f-Fc fusion protein as a reagent to block the interaction of CD300f with its ligands, and siRNA technology, it has also been shown that this receptor inhibits DC-induced T cell proliferation in vitro. Furthermore, CD300f negatively regulates DC-initiated antigen-specific T cell responses both in vivo and in vitro, and inhibits antigen-specific Th1 and CTL responses in vivo. 51 A feature of CD300f is that also exhibits an activating potential that is more evident when CD300f is cross-linked in cells that express receptors with mutated ITIMs. [53] [54] For human CD300f, both tyrosines within the two PI3K binding motifs recruit the p85α subunit of PI3K, and SHP-1 does not block its recruitment. 53 In addition to PI3K, CD300f also binds Grb2. The recruitment of the p85α subunit of PI3K and Grb2 to the cytoplasmic tail of mouse CD300f has been demonstrated by some authors, 54 but not by others. 11 Intriguingly, cross-linking of mouse CD300f was able to induce IL-6 production in cells expressing a CD300f construct with all the intracellular tyrosines mutated to phenylalanine, 54 an effect that was not observed with human CD300f. 53 This prompted the search for partners of mouse CD300f that are responsible for the activating signal. In fact, the FcRγ chain was shown to associate with mouse CD300f, and more importantly it was shown that FcRγ chain deficient BMMCs expressing CD300f with all the tyrosine residues mutated were severely impaired in their ability to produce IL-6. 54 Moreover, cross-linking of wild type mouse CD300f enhanced IL-6 production of BMMCs stimulated by LPS, in a process dependent on the intracellular tyrosines and the FcRγ For personal use only. on November 16, 2017. by guest www.bloodjournal.org From chain. On the other hand, cross-linking of wild type mouse CD300f suppressed IL-6 cytokine production in response to other TLR agonists or SCF. 54 Thus, the mouse inhibitory receptor CD300f has a unique property to associate with FcRγ chain and thereby functions as an activating receptor in concert with TLR4 stimulation. Lastly, mouse CD300f has also been shown to enhance phagocytosis of apoptotic cells when expressed in the fibroblast cell line L929, although the signaling intermediates involved in this signaling pathway are not known. 59 An additional and intriguing aspect of mouse CD300f is its ability to mediate apoptosis on myeloid cells. Cross-linking of CD300f with mAbs mediated cell death that was dependent on the cytoplasmic tail but did not require intact ITIMs or PI3K activity.
CD300f mediated apoptosis was caspase, ER stress and autophagy independent. 60 More studies are required to further delineate the ability of mouse CD300f to regulate cell survival and to show if human CD300f has a similar property.
Human non-ITIM Containing CD300 Receptors
Human CD300b transcripts are detected in myelomonocytic cells and weakly in some NK and B cell lines. [61] [62] All-trans-retinoic acid in combination with PMA increases the expression of CD300b in THP-1 cells. 62 CD300b contains a lysine in the transmembrane segment that is required for its association with DAP10 and DAP12. 61, 63 It also has a Grb2 binding motif in the cytoplasmic tail that is tyrosine phosphorylated and is able of recruiting Grb2. 61 The phosphorylation of the Grb2 motif was observed in DAP12-/-, but not DAP12+/+ BMMCs transduced with CD300b. 63 Accordingly, in the presence of DAP12, the Grb2 binding motif does not mediate activation signals, and other signaling pathways, e.g. those involving hexosaminidase granule release, were only activated when DAP12 was present, 61, 63 suggesting that this adaptor is the main contributor to human CD300b-mediated signal. The Grb2 binding motif was sufficient for transmitting activation signals when human CD300b was expressed in the DAP12-negative RBL-2H3 cells, 61 and in DAP12 or DAP10/DAP12 double deficient BMMCs. 63 An additional unidentified adaptor has been proposed since under certain experimental conditions, the absence of both DAP12 and DAP10 in combination with the mutated cytoplasmic tyrosine, did not completely inhibited the activating signal, while it was completely abrogated when the transmembrane lysine was mutated to a glutamine. 63 Like CD300a, transcripts encoding CD300c are found in almost all leukocytes. 9 CD300c transcription is down-regulated in pDCs in response to TLR7 and TLR9 stimulation. 24 The ligation of CD300c expressed in RBL-2H3 cells with Abs is able to deliver activating signals that are mediated by the transmembrane glutamic acid residue and by its association with FcRγ chain. 20 CD300d transcripts are found in the myeloid compartment. However, CD300d is not expressed on the cell surface of primary cells, suggesting a mechanism that regulates the trafficking of this receptor in human cells. It can be expressed on the cell surface of COS-7 when co-transfected with FcRγ chain. However, it is not detected on the surface of cells that normally express FcRγ chain and have CD300d mRNA. 19 CD300d associates with other CD300 molecules and is able to decrease the cell surface expression of CD300f
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From when both of them are expressed in COS-7 cells. 19 Differentiation of monocytes towards macrophages was accompanied with a decrease in the levels of CD300d mRNA, particularly in IL-13 driven type II macrophages. 19 The ability of CD300d to deliver activating signals is not known. 19
CD300e is expressed on the cell surface of monocytes and circulating mDCs in vivo, although it is expressed at low levels in in vitro-derived macrophages and DCs. [64] [65] [66] It has a lysine in the transmembrane segment allowing its association with DAP12. 64 Crosslinking of CD300e with mAbs was able to induce activation signals, such as NFAT transcriptional activity, Ca ++ mobilization and release of reactive oxygen species in monocytes. [64] [65] It also induced cytokine release, expression of activation markers, and promoted survival of monocytes and circulating mDCs. [64] [65] Additionally, DCs activated via CD300e exhibited a higher capacity to stimulate T cells. 65 
Mouse non-ITIM Containing CD300 Receptors
CD300lb/LMIR-5/CLM-7/mIREM-3 transcripts are found in myeloid cells and are expressed on the surface of granulocytes, DCs, macrophages and mast cells. 63 Neutrophils constitutively shed a soluble form of CD300lb/LMIR-5/CLM-7/mIREM-3 in vitro and in vivo, in a process mediated by MMPs, and TLR4 stimulation increased its release. 67 DAP12 plays the major role in delivering the activating signals, and to a lesser extent DAP10. 63, 68 Engagement of the receptor with Abs induced ERK, p38 and Akt phosphorylation, cytokine and chemokine production, cell adhesion, histamine release and mast cells survival. 63 The cross-linking of endogenous CD300lb/LMIR-5/CLM-7/mIREM-3 with Abs induced Syk-dependent activation of fetal liver mast cells. 63 Its engagement by T cell Ig mucin (TIM)-1, its ligand, also induced ERK phosphorylation in CD300lb/LMIR-5/CLM-7/mIREM-3 transduced BMMCs and IL-6 production. 68 MAIR-II/LMIR-2/CLM-4/DIgR1 transcripts are found in myeloid cells and in B cells. 10, [12] [13] On the cell surface, it is found on BM-derived DCs, BMMCs, peritoneal macrophages and subsets of B cells. 10, [12] [13] LPS treatment up-regulated its expression in splenic B cells and in macrophages through a mechanism involving the enhancement of FcRγ chain expression. 13, 69 MAIR-II/LMIR-2/CLM-4/DIgR1 possesses a lysine in the transmembrane region that is important for its association with adaptor proteins. 69 DAP12, DAP10 and FcRγ chain have been shown to interact with MAIR-II/LMIR-2/CLM-4/DIgR1 when they are expressed in COS1 cells. 12 However, it associates only with endogenous DAP12 in transfected RAW cells and in splenic B cells and macrophages. 13, 69 In peritoneal macrophages it associates with endogenous DAP12 and FcRγ chain. 69 in the endosomal/lysosomal compartments and not on the cell surface. 72 The reason for these discrepant results is not clear, although it may be related to the techniques used to detect the expression of LMIR-7/CLM-3. This receptor associates with FcRγ chain although it does not possess a charged residue in the transmembrane domain. 71 Crosslinking of LMIR-7/CLM-3 on transduced BMMCs induced activation signals and cytokine and chemokine production. These activation signals were abolished when the receptor was cross-linked in FcRγ chain deficient BMMCs. 71 Interestingly, as a result of its endosomal/lysosomal localization, it has been shown that LMIR-7/CLM-3 functions as a positive regulator of TLR9, but not of TLR4 or TLR3. 72 Results from transfected cells and knock down experiments in peritoneal macrophages, showed that LMIR-7/CLM-3 upregulates TLR9-mediated production of the proinflammatory cytokines TNF-For personal use only. on November 16, 2017. by guest www.bloodjournal.org From α and IL-6, but does not affect type I IFN expression. 72 Further confirmation of LMIR-7/CLM-3-mediated effects on TLR9 signals was obtained by using macrophages derived from LMIR-7/CLM-3 transgenic mice. 72 What is more, the LMIR-7/CLM-3-mediated promotion of TLR9 production of proinflammatory cytokines was through a mechanism that involves the ubiquitination of TRAF6, a signaling mediator of TLR-triggered NF-κB and MAPKs activation. 72 CLM-5/LMIR-4/MAIR-IV transcripts are detected in myeloid cells. 52, 73 On the cell surface is expressed on granulocytes, monocytes, macrophages, and in BM-derived mDCs and pDCs. 52, 74 While LPS down-regulated CLM-5/LMIR-4/MAIR-IV expression on neutrophils, GM-CSF increased it. 52 . Notwithstanding that CLM-5/LMIR-4/MAIR-IV has a charged transmembrane residue it seems that it is not required for its association with FcRγ chain. 52, [73] [74] In fact, the interaction of CLM-5/LMIR-4/MAIR-IV with FcRγ chain depends on the extracellular juxtamembrane region as well as its transmembrane domain. 71 The critical role of FcRγ chain in CLM-5/LMIR-4/MAIR-IV-mediated signaling transmission was shown by the complete absence of activation signals in FcRγ chain deficient BMMCs following ligation with antibodies. 52 Lyn and Syk kinases are also involved in CLM-5/LMIR-4/MAIR-IV signal transmission. 52 Engagement with mAbs in BMMCs transduced with the receptor induced IL-6 production, histamine release and delivered an anti-apoptotic signal. Additionally, combination of CLM-5/LMIR-4/MAIR-IV, TLR4 and FcεRI stimulations synergistically increased cytokine production by BMMCs. 52 In neutrophils and peritoneal macrophages it also induced proinflammatory cytokines production after cross-linking with mAbs. 74 For personal use only. on November 16, 2017. by guest www.bloodjournal.org From
Ligand Recognition of the CD300 Molecules
To search for cells expressing the ligands for the CD300 molecules, several groups have utilized CD300-Fc chimeric proteins as a tool. 42, 51, [58] [59] [75] [76] [77] An interesting finding was that both CD300a-Fc and CD300f-Fc bind to dead cells from several species in a Ca ++ dependent manner, 42, 59, 76 suggesting that these two receptors must bind evolutionary conserved ligands.
Apoptotic/dead cells are characterized by changes in the plasma membrane, including the loss of phospholipid asymmetry. 78 From the early stages of apoptosis cells expose PS and PE in the outer leaflet of the plasma membrane, [78] [79] [80] [81] [82] acting as "eat-me" signals and leading to their engulfment by phagocytes. [83] [84] The binding of CD300a-Fc to dead cells was blocked by MFG-E8, a ligand for PS, and by duramycin, a ligand for PE. 42, 76 Subsequent experiments, using a variety of techniques showed the direct binding of CD300a-Fc to purified PS or PS containing liposomes. 42, 76 In addition, human CD300a-Fc was also shown to bind purified PE and PE containing liposomes, exhibiting a stronger binding than that to PS. 76 The functional recognition of purified PE was shown in a system using reporter cells expressing a CD300a-CD3ζ chimeric receptor. 76 The binding of CD300a-Fc to PE immobilized on a membrane was not observed in another study, although it is not clear if the authors used human CD300a-Fc or mouse CD300a-Fc in their experiments. 42 This is an important issue since a different publication has reported that mouse CD300a-Fc does not bind to any lipid. 85 To identify the residues that are involved in human CD300a binding to PS and PE, a molecular model was generated
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From based on the crystal structure of TIM-4 complexed with PS. 76, 86 The crystal structure of human CD300a is known, 14 and the metal ion and a molecule of PS or PE were placed in positions corresponding to the PS bound to TIM-4 structure. The model showed that PE and PS interact with CD300a residues that form a cavity where the hydrophilic heads of the lipids can penetrate. 76 Early studies showed that mouse CD300f-Fc bound strongly to CD4 + T cells and weakly to CD8 + T cells. 51 However, these results were not reproduced by others. 77 In another study, it was shown that CD300f-Fc binds to apoptotic cells, suggesting that CD300f also recognizes phospholipids exposed on the outer leaflet of the plasma membrane of dead cells. Indeed, this binding was blocked when the PS ligand Annexin V was present in the assay. 59 In addition, CD300f-Fc exhibited binding to a subset of activated T cells that was also blocked by Annexin V, correlating with the exposure of PS on the surface of activated lymphocytes, including T and B cells. 59, [87] [88] The capability of CD300f-Fc binding to purified PS and PS containing liposomes was demonstrated using ELISA, ultracentrifugation and surface plasmon resonance (SPR) assays. 59 Another PS ligand, i.e. MFG-E8, is able to block the binding of mouse CD300f-Fc to purified PS coated on a plate. 59 Recently, another group has published that mouse CD300f-Fc binds only to ceramide immobilized on a membrane, but surprisingly, it did not bind other lipids, including PS, PE, SPC or phosphatidylcholine (PC). 58 However, the same authors found that the same recombinant protein binds ceramide, PC, SPC, HDL, and LDL coated on a plate, and that reporter cells expressing a mouse CD300f-CD3ζ chimeric receptor functionally recognized the same group of lipids, but not PS or PE. 58 It is important to 59 Other studies have shown that human CD300f-Fc and rat CD300f-Fc are also able to bind cells from the CNS. 75 The identity of the CD300f ligand expressed in these cells remains unknown. Finally, in an ELISA assay with purified immobilized lipids on a plate and mouse CD300-Fc recombinant proteins, a study found that mouse CD300 receptors have overlapping, but distinctive patterns, of lipid binding specificity. 85 In addition, in a reporter cell assay, CD300lb/LMIR-5/CLM-7/mIREM-3 was shown to functionally recognize lipids. 85 However, some of the results from this study are not in complete agreement with those obtained by others. 42, [58] [59] The reason for the discordant results between the different publications is currently unknown, and without a doubt more studies are required to characterize the fine specificity of lipid binding by the CD300 molecules.
What are the consequences and the significance of binding lipids by the CD300 molecules? Given that both PS and PE are expressed on dead cells, [78] [79] [80] [81] [82] [83] [84] the role of CD300a and CD300f in the removal of apoptotic cells has been studied. 43, 59, 76 Expression of mouse CD300f enhanced phagocytosis of apoptotic cells by the fibroblast cell line L929. 59 Since CD300f has been shown to work mostly as an inhibitory receptor, 11, 46 it is unclear how this receptor promoted phagocytosis. One possible explanation might be that the amount of SHP-1, a phosphatase mostly expressed in hematopoietic cells, is very low in L929 cells and not able to block the PI3K-mediated activation signal that is also generated after ligation of CD300f. [53] [54] Undoubtedly, experiments in primary cells expressing CD300f are required to determine if this receptor promotes, or rather, blocks For personal use only. on November 16, 2017. by guest www.bloodjournal.org From the phagocytosis of apoptotic cells in physiological conditions. On the other hand, human CD300a inhibits the uptake of apoptotic cells by monocyte-derived macrophages and by CD300a expressing L929 cells 76 . Defective removal of dead cells has deleterious consequences for the host, leading to the development of autoimmunity. 83 The nature of the immune response to cell death depends on which, where and how cells die, and what immune cells interact with them. 89 Variations in these parameters will determine whether cell death is immunogenic, tolerogenic or silent. 89 It is possible that the CD300 family of receptors may play a central role in determining the outcome of the immune response when dead cells interact with different components of the immune system. Indeed, recently published data support this hypothesis. 43, [67] [68] For instance, CD300a inhibited the cytokine production by LPS stimulated mast cells and macrophages in the presence of apoptotic cells. 43 Extracellular ceramides are abundant in stomach, skin and brain. In the skin, they are abundant in the epidermis, whereas disseminated or patchy expression is also found in the dermis, in the vicinity of mast cells. 58 In wild type mice, the administration of an anticeramide Ab increased the FcεRI-mediated passive cutaneous anaphylaxis (PCA) reactions, whereas administration of ceramide liposomes diminished the PCA responses.
The administration of both reagents had no effect in the CD300f-/-mice, indicating that the interaction between extracellular ceramides and CD300f negatively regulates FcεRImediated mast cell activation. 58 For personal use only. on November 16, 2017. by guest www.bloodjournal.org From TIM-1 and TIM-4 have been proposed as the endogenous ligands for CD300lb/LMIR-5/CLM-7/mIREM-3. 68 Interestingly, the binding of a CD300b-Fc protein to cells expressing TIM-1 with mutated WFND metal-ion PS-binding motif was completely abolished. 68 Although this finding may suggest that CD300lb/LMIR-5/CLM-7/mIREM-3 could interact with PS, it was shown that CD300b does not bind to phospholipids, does not promote phagocytosis of apoptotic cells, and does not affect TIM-1 or TIM-4mediated phagocytosis. 68 These results are in contradiction with those showing that CD300lb/LMIR-5/CLM-7/mIREM-3 binds a specific pattern of lipids, including PS, PE and PC. 85 Different methods used to determine the binding of the receptor to lipids may explain these opposing results. Nevertheless, very recently it has been proposed that an interaction between mouse CD300lb-Fc and an unidentified ligand, other than TIM-1 and TIM-4, is involved in CD300lb-Fc induced cytokine production by peritoneal macrophages. 67
Disease Relevance of the CD300 Molecules
The expression of CD300a on mast cells, eosinophils and basophils, three important cell types involved in the initiation and regulation of allergic responses, led to the design of bispecific antibody fragments targeting CD300a along with other receptors with the goal of down-regulating the function of these cells during disease conditions. 90 Linking CD300a with c-Kit by a bispecific antibody fragment completely abrogated mast cell degranulation induced by SCF in a murine model of cutaneous anaphylaxis. 44 Another bispecific antibody fragment linking CD300a to IgE bound to FcεRI (specific for mast cells and basophils), abolished the allergic and inflammatory responses in two different For personal use only. on November 16, 2017. by guest www.bloodjournal.org From animal models, i.e. IgE dependent PCA and ovalbumin induced acute experimental asthma. 45 A third bispecific antibody fragment linking CD300a to CCR3 (specific for mast cells and eosinophils) was shown to reduce eosinophil signaling in vivo, to inhibit bronchoalveolar lavage fluid (BALF) inflammation, eosinophil and mast cell mediator release, eosinophil-derived TGF-β1 in the BALF and lung remodeling, and very importantly, it reversed lung inflammation in a model of chronic established asthma. 91 Also, in a model of allergic peritonitis, neutralization of CD300a resulted in a significant increase of inflammatory mediators and eosinophilic infiltration. 33 Finally, it has been shown that the basal expression of CD300a on basophils from birch pollen allergic patients is significantly lower than in healthy control individuals. 36 Altogether, these results indicate that CD300a functions as an inhibitory receptor in vivo and that it is a potential target for treatment of allergic diseases. In addition to their role in allergic processes, mast cells are also known to play an important role in a cecal ligation and puncture (CLP) peritonitis model in mice, 92 where a large number of cells undergo apoptosis in the peritoneal cavity. 93 After CLP, CD300a deficient peritoneal mast cells produced more chemoattractants, leading to increased neutrophil recruitment and better bacterial clearance. As a consequence CD300a-/-mice showed prolonged survival. 43 These results indicate that CD300a regulates mast cell inflammatory responses to microbial infections.
The CD300 gene complex has been linked to PSOR2, a susceptibility locus for psoriasis. [94] [95] A single nucleotide polymorphism (SNP) that encodes for a nonsynonymous polymorphism (R94Q) within the Ig domain of CD300a, has been associated with susceptibility to psoriasis, 94 although subsequent studies have disputed this linkage. Nevertheless, it is important to mention that the surface expression of CD300a on CD4 + T cells is lower in psoriatic patients compared to healthy controls, 27 and that a CD300a-Fc recombinant protein with arginine at position 94 binds better to dead cells and to PE and PS, than a protein with glutamine at position 94. 76 Other genetic association studies have shown that CD300a may be involved in the etiology of Alzheimer 's disease. 96 In combination with other three genes, CD300a has been proposed as a blood based biomarker that can differentiate ulcerative colitis from Crohn's disease and noninflammatory diarrhea. 97 This may help the current serologic testing for inflammatory bowel disease that is based on reactivity to bacterial antigens and not host gene expression. 98 In genome wide expression studies of lymphoblasts compared to normal CD19 + CD10 + B cell progenitors, CD300a was identified, along with other markers, to be differentially expressed in acute lymphoblastic leukemia. 99 Sixteen differentially expressed markers, including CD300a, were validated for minimal residual disease detection by 4-color flow cytometry analysis including antibodies against CD19, CD10 and CD34 and one of the new markers. 99 During HIV infection the expression of CD300a on B cells is deregulated, suggesting the possibility that this receptor may contribute to the B cell dysfunction observed in HIV infected patients. 30 Also, in HIV specific CD8 + T cells it was found that the expression of the transcription factor BAFT significantly correlates with the expression of CD300a and For personal use only. on November 16, 2017. by guest www.bloodjournal.org From other inhibitory receptors. 26 BAFT is up-regulated in PD-1 + exhausted HIV specific CD8 + T cells and inhibits T cell function, probably by a mechanism that involves, among others, increased expression of inhibitory receptors such as CD300a. Finally, it has been reported that the frequency of CD8 + CD300a + T cells, that are mainly effector and effector/memory CD8 + T cells, is increased in the blood of pregnant women with chronic chorioamnionitis. 31 However, the biological significance of this finding is unknown.
In a model of multiple sclerosis, CD11b + CD11c + CD300f + cells derived from circulating inflammatory monocytes are recruited to the areas of inflammation in the CNS. These cells express iNOS and TNF-α. CD300f-/-mice or animals treated with a CD300f-Fc fusion protein presented a more severe disease without an increase in the incidence. This was characterized by an augmented release of myeloid-specific inflammatory mediators and an exacerbated demyelination. Lack of CD300f does not affect T cell priming, indicating that this receptor regulates disease severity at the effector phase by suppressing the release of reactive oxygen species and inflammatory cytokines from myeloid effector cells. 77 The neuroprotective role of CD300f has also been shown in a rat model of acute brain injury. 75 Injection of N-methyl-D-aspartate (NMDA) into the striatum and cortex of rats induced an acute excitotoxic injury that was significantly reduced if a modular recombinant gene therapy vector bound to plasmids encoding human or rat CD300f were introduced into the lesion site. 75 Although CD300f-/-mice show normal mast cell development, the absence of the receptor led to exacerbated mast cell-dependent allergic responses. These include enhanced FcεRI-mediated passive systemic anaphylaxis and PCA, and mast cell dependent airway inflammation and atopic dermatitis. In this context, For personal use only. on November 16, 2017. by guest www.bloodjournal.org From it is important to note that chronically inflamed skin and lungs tend to have higher levels of extracellular ceramides, a ligand for mouse CD300f. 58 Down-regulation of CD300f in DCs with siRNA was shown to enhance the antitumor effect of immunization protocols in a mouse model of cancer. 51 Korver et al. have generated anti-human CD300f antibodies that show complement-dependent cytotoxicity and antibody-dependent cell cytotoxicity activities in vitro against CD300f expressing AML derived cell lines and freshly isolated blasts from AML patients. 48 In addition, these antibodies exhibited an antigrowth effect in an established HL-60 xenograft tumor model and they significantly reduced the engraftment of primary human AML cells. 48 These studies highlight the potential of targeting CD300f in tumor immunotherapy.
In a model of renal ischemia/reperfusion, TIM-1 expression in the kidney was induced, and CD300lb/LMIR-5/CLM-7/mIREM-3 expressing neutrophils were recruited causing renal tubular damage. Both the recruitment of neutrophils and the kidney damage were significantly reduced in CD300lb/LMIR-5/CLM-7/mIREM-3 deficient mice, indicating a role for this receptor in these processes. 68 In addition, it has been reported that a soluble form of CD300lb/LMIR-5/CLM-7/mIREM-3 has a role in LPS induced sepsis. 67 
Future Considerations
The development of better reagents to unequivocally detect and quantify the expression of the different members of the CD300 family is of great need. Another important area of future research should be the identification of ligands for the still "orphan" receptors, especially human CD300 molecules. Little is known about the topology of PS and PE exposed on apoptotic cells and how they are engaged by specific receptors, including the CD300 molecules. Furthermore, there is no information on whether CD300 receptors recognize ligands as monomers, dimers, or higher order oligomers. We are at the start point of understanding the role of the CD300 family of receptors in disease settings, the possibility of using them as biomarkers, and their potential as therapeutic targets. In light of the preclinical data obtained from mouse models, we need to know more about the involvement of the CD300 family in human diseases such as cancer, sepsis, and autoimmune and allergic diseases. Through their binding to lipids, the CD300 family forms an arrayed receptor system that is able to recognize the viability and activation status of cells, and consequently have a significant influence on the final outcome of the immune response. 
